Davita Inc (NYSE:DVA) saw unusually large options trading on Wednesday. Investors acquired 3,355 call options on the stock. This is an increase of approximately 1,723% compared to the average daily volume of 184 call options.
Shares of Davita (DVA) traded up $1.06 on Friday, hitting $72.97. The stock had a trading volume of 1,863,520 shares, compared to its average volume of 1,200,953. The company has a market cap of $13,375.40, a P/E ratio of 28.07 and a beta of 0.99. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. Davita has a 12-month low of $52.51 and a 12-month high of $80.71.
In other Davita news, CEO Javier Rodriguez sold 22,532 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $67.48, for a total value of $1,520,459.36. Following the completion of the transaction, the chief executive officer now owns 210,317 shares in the company, valued at approximately $14,192,191.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Leanne M. Zumwalt sold 949 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $68.19, for a total value of $64,712.31. Following the completion of the transaction, the vice president now owns 12,423 shares of the company’s stock, valued at approximately $847,124.37. The disclosure for this sale can be found here. In the last three months, insiders sold 121,509 shares of company stock valued at $8,310,388. 2.10% of the stock is currently owned by insiders.
Several research analysts have commented on the company. Robert W. Baird restated a “buy” rating and issued a $95.00 target price (up previously from $82.00) on shares of Davita in a research note on Friday, January 12th. Bank of America restated a “buy” rating and issued a $92.00 target price (up previously from $85.00) on shares of Davita in a research note on Thursday, January 11th. TheStreet upgraded Davita from a “c” rating to a “b-” rating in a research report on Thursday, January 4th. Zacks Investment Research upgraded Davita from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research report on Tuesday, February 6th. Finally, SunTrust Banks set a $75.00 price target on Davita and gave the company a “hold” rating in a research report on Thursday, December 21st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $78.60.
WARNING: “Davita Sees Unusually High Options Volume (NYSE:DVA)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/11/davita-sees-unusually-large-options-volume-dva.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.